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Effect of walnut consumption on markers of blood glucose control: A systematic
review and meta-analysis
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease increasing in global prevalence. While habitual
consumption of walnuts is associated with reduced risk of cardiovascular disease, there is inconsistent
evidence for the impact of walnut consumption on markers of glycaemic control. This systematic review
and meta-analysis aimed to examine the effect of walnut consumption on markers of blood glucose
control. A systematic search of Medline, PubMed, CINAHL and Cochrane databases (to 2nd March 2019)
was conducted. Inclusion criteria were randomised controlled trials conducted with adults which
assessed the effect of walnut consumption on: fasting blood glucose and insulin, glycated haemoglobin,
and Homeostatic Model Assessment of Insulin Resistance. Random effects meta-analyses were
conducted to assess the weighted mean differences (WMD) for each outcome. Risk of bias in studies
was assessed using the Cochrane Risk of Bias tool 2.0. Sixteen studies providing 18 effect sizes were
included in the review. Consumption of walnuts did not result in significant changes in fasting blood
glucose levels (WMD: 0.331 mg/dL [95% confidence intervals: -0.817, 1.479]) or other outcome measures.
Studies were determined to have either 'some concerns' or be at 'high risk' of bias. There was no evidence
of an effect of walnut consumption on markers of blood glucose control. These findings suggest that the
known favourable effects of walnut intake on cardiovascular disease are not mediated via improvements
in glycaemic control. Given the high risk of bias observed in the current evidence base, there is a need for
further high quality randomised controlled trials.
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Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease increasing in global prevalence. While
habitual consumption of walnuts is associated with reduced risk of cardiovascular disease,
there is inconsistent evidence for the impact of walnut consumption on markers of glycaemic
control. This systematic review and meta-analysis aimed to examine the effect of walnut
consumption on markers of blood glucose control. A systematic search of Medline, PubMed,
CINAHL and Cochrane databases (to 2nd March 2019) was conducted. Inclusion criteria
were randomised controlled trials conducted with adults which assessed the effect of walnut
consumption on: fasting blood glucose and insulin, glycated haemoglobin, and Homeostatic
Model Assessment of Insulin Resistance. Random effects meta-analyses were conducted to
assess the weighted mean differences (WMD) for each outcome. Risk of bias in studies was
assessed using the Cochrane Risk of Bias tool 2.0. Sixteen studies providing 18 effect sizes
were included in the review. Consumption of walnuts did not result in significant changes in
fasting blood glucose levels (WMD: 0.331 mg/dL [95% confidence intervals: -0.817, 1.479])
or other outcome measures. Studies were determined to have either ‘some concerns’ or be at
‘high risk’ of bias. There was no evidence of an effect of walnut consumption on markers of
blood glucose control. These findings suggest that the known favourable effects of walnut
intake on cardiovascular disease are not mediated via improvements in glycaemic control.
Given the high risk of bias observed in the current evidence base, there is a need for further
high quality randomised controlled trials.
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Introduction
Nutrition plays an increasingly important role in the prevention of chronic diseases including
coronary heart disease and type 2 diabetes mellitus (T2DM) (1,2). The global prevalence of
T2DM is increasing. In 2017, 424.9 million adults globally had diabetes, and this is projected
to increase to 628.6 million by 2045 (3). Research has demonstrated that lifestyle strategies
such as dietary changes are effective for the prevention and management of T2DM (4). While
dietary patterns exert the effect, they are the sum of individual food choices. There is
therefore a need to establish the evidence for individual foods which may aid in the
prevention of T2DM, as well as improve disease management for persons already diagnosed.
Walnuts are part of the nut category of foods but stand out for their high polyunsaturated fatty
acid content (5) which is aligned to cholesterol lowering effects. This, and other components
in walnuts and nuts generally contribute to reduced risk of coronary heart disease. For the
food category of nuts, habitual consumption has been associated with the reduced risk of
coronary heart disease (6-10) but the evidence base for T2DM is less consistent. Recent
systematic reviews of observational and clinical studies have reported conflicting results,
with an inverse relationship between nut intake and risk of T2DM found by one review (7),
yet no association reported in others (6,8,11). Inconsistent results have also been reported when
the effect of nut consumption on markers of glycaemic control has been investigated. In a
systematic review restricted to individuals with T2DM, nut consumption was found to
improve glycated haemoglobin (HbA1c) and fasting glucose levels, with no impact on fasting
insulin or homeostasis model assessment of insulin resistance (HOMA-IR) (12). Conversely,
favourable effects of nut intake on fasting insulin and HOMA-IR were found in another
review, although no effect on HbA1c or fasting glucose was found (13). To our knowledge, an
umbrella review of systematic reviews specifically exploring the effect of nut consumption in
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T2DM or markers of glycaemic control has not been conducted to clarify these inconsistent
results.
Given the variation in composition of different types of nuts, there is value in considering the
impact of individual nut categories. As stated earlier, walnuts, are distinguishable from other
nuts by virtue of a high polyunsaturated fatty acid content, including alpha-linolenic acid,
while also delivering dietary fibre and phytochemicals (5,14). A past analysis of the Nurses’
Health Study found increased consumption of walnuts was associated with reduced incidence
of T2DM, although the relationship may be partly mediated by body mass index (15). There
may be a number of reasons for this observation. For example, secondary analysis from
dietary trials (16,17) demonstrated that provision of walnuts appeared to support changes in
overall diet quality. Here, the consumption of walnuts could be implicated in whole-of-diet
effects for behavioural as well as biological reasons. With these issues in mind, the aim of
this systematic review and meta-analysis was to examine the effect of walnut consumption on
markers of blood glucose control (fasting blood glucose, fasting insulin, HbA1c, and HOMAIR) in adults.

Methods
This systematic review was conducted according to the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions (18), and was reported according to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement
(19)

(Supplementary Data 1). The protocol for the review was prospectively registered with

PROSPERO, the International Prospective Register of Systematic Reviews
(https://www.crd.york.ac.uk/prospero/, CRD42019123636).
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Study eligibility
To be eligible for inclusion in this review, studies were required to meet the following
inclusion criteria: (1) randomised controlled trial study design (including parallel and
crossover designs, and studies where participants were randomised at either the individual or
cluster level); (2) studies conducted with humans aged 18 years or older; (3) studies assessing
the effect of consuming walnuts (as a whole or processed nut, or oil form) on biological
markers of blood glucose control (fasting blood glucose, HbA1c, fasting insulin, HOMA-IR);
(4) studies where the effect of walnut consumption could be isolated from other food sources
or interventions such as physical activity programs. Eligible studies were not limited to those
published in English, or by study duration.
Data sources
A systematic search of the databases MEDLINE (EBSCO), PubMed, Cumulative Index to
Nursing and Allied Health Literature (EBSCO) and Cochrane Central Register of Controlled
Trials was conducted by EN. Date restrictions were not applied, and the databases were
searched on 2 March 2019. Both MEDLINE and PubMed were searched to ensure recent
studies were detected, in line with recommendations by Rosen and Suhami (20). Where
possible Medical Subject Headings in addition to free-text search terms were used in the
search (20). Reference lists of eligible articles and relevant review articles were also reviewed
for potential studies. An example of the search strategy is available in Supplementary Data 2.
Articles were initially processed using Endnote X8 (2017, Endnote X8.1 [software])
including removal of duplicates, before being transferred into Microsoft Excel (2016,
Microsoft Excel version 16.0 [software]) for screening and full text review.
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Study selection
Articles were screened in duplicate based on the title and abstract. In the case that an abstract
was not available or did not provide sufficient information to draw a conclusion regarding
eligibility, the full text articles were retrieved for further review. Following screening, full
text articles were reviewed in duplicate against the eligibility criteria. In the case that multiple
articles reported results from a single study, all associated articles were checked to avoid
duplication of study populations in the analysis. Where multiple articles reported different
information for the outcomes of the same study, all relevant articles were included and linked
together, as recommended by the Cochrane Handbook (18). When multiple articles reported
the same outcomes from a single study, the article reporting the longest follow up period was
included in the review.
Data extraction
The following data were extracted from each study: citation, country, study design, sample
size, participant age and body mass index, participant health status, study duration, walnut
form, dose of walnuts, details of control arm, background diet, and the percentage dietary fat
consumed in the intervention diet. Aggregate outcome data was extracted from each study.
Where possible, the mean changes in the relevant biomarker outcomes and the respective
standard deviation (or standard error/95% confidence interval) were obtained. When these
data were not available, the mean final values and the respective standard deviation (or
standard error/95% confidence interval) were retrieved as outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (18). Where median and interquartile range were
provided, these were converted to mean and standard deviation using the formula developed
by Wan et al. (21). As one study (22) provided only pooled standard error for the intervention
and the control groups, this pooled standard error was used for both groups. In the case that
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the published study did not provide adequate information, study authors were contacted for
additional details. Where available, data from intention-to-treat analyses was extracted for
use in the meta-analysis. Where this was not available, data from per protocol analyses were
used, and the impact of these approaches on study results were considered in the risk of bias
assessment (outlined below).
Abstract screening, full text review, and data extraction were conducted independently by
two authors (EN and VG), with any disagreements were resolved via consensus. Where
consensus could not be reached a third author was consulted (YP).
Risk of bias assessment
The Cochrane Collaboration Risk of Bias tool 2.0 (23) was used to determine the risk of bias in
the included studies, with the effect of assignment to the interventions considered. EN and
VG independently appraised the risk of bias and disagreements were resolved by discussion
until consensus was reached.
Data synthesis
Stata IC (version 15.1, StataCorp LLC, USA) was used to conduct random effects metaanalyses, using the metan command (using the randomi option for random effects). This
command uses the DerSimonian and Laird method with the heterogeneity estimate taken
from the inverse variance fixed effect model(24,25). Sensitivity analyses were also conducted
using the random-effects model with Hartung-Knapp-Sidik-Jonkman adjustment(26).
Weighted mean differences (with 95% confidence intervals) in change or final mean values
for each outcome were calculated. As both parallel and cross-over studies were included in
the review, both study designs were initially analysed the same way, using a paired analysis.
This approach was used as it is the most conservative method for managing cross-over
studies in meta-analysis (18). In addition, sensitivity analyses were conducted using paired
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analysis of cross-over studies with correlation coefficients of 0.25, 0.5, and 0.75, in order to
determine if this analysis underweighted the cross-over studies, as conducted in our previous
review on nuts as a food group (27). In the case of two studies which included more than one
eligible intervention group and corresponding control groups(17,28), study groups were
included in meta-analyses as separate effect sizes. Sensitivity analyses were then further
conducted to examine the effect of pooling these separate study groups on results. Metaanalyses were conducted using available cases analyses, with attrition addressed as part of the
risk of bias assessment (outlined below).
The I2 test statistic was used to estimate the proportion of total variation attributable to the
between-study heterogeneity (29). In line with the guidance of Higgins et al.(29), I2 values of
25%, 50%, and 75% were taken to indicate low, moderate, and high heterogeneity. Contour
funnel plots were created to determine the presence of small study effects for outcomes with
10 or more effect sizes(30). An Egger’s test was then conducted to examine the extent of
funnel plot asymmetry (31). ‘Leave-one-out’ sensitivity analyses were conducted to explore
the effect of removing each individual study from the meta-analyses. In addition, to explore
the effects in whole walnuts only, sensitivity analyses were conducted excluding studies
using walnut oil(28,32). Pre-specified sub-group analyses (based on study quality, study
duration (less than three months versus more than three months, aligning with the approaches
used in previous meta-analyses of nut consumption(12,33)), and health status of participants)
were conducted to explore differences in the magnitude of effects between the sub-groups. In
addition, post hoc sub-group analyses were conducted based on the dose of walnuts
consumed (<50 g per day vs >50 g per day, based on dose sub-groups used in a previous
meta-analysis of nut consumption (33)), and the percentage of total dietary fat provided by the
intervention diet (<37% vs >37% per day, based on previous research which found beneficial
effects of fat substitution at total fat intakes <37%(34)). Sub-group analyses were conducted

Downloaded from https://www.cambridge.org/core. University of Wollongong, on 06 May 2020 at 00:29:14, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114520001415

Accepted manuscript

where there were at least 10 effect sizes per outcome in total (18), although the number of
effect sizes per individual sub-group were not restricted. The relationship between the nut
dose (in studies exploring whole nuts only) and the study duration, as continuous
characteristics, were then explored via random-effects meta-regression using the metareg
command(35) which uses the Knapp-Hartung variance estimator(36), where sample size
permitted, as recommended by the Cochrane Handbook (18).
Quality of the body of evidence
The quality of the body of evidence (also known as certainty) was then determined using
GRADE (37) (GRADEpro GDT: GRADEpro Guideline Development Tool [Software].
McMaster University, 2015 [developed by Evidence Prime, Inc.]. Available from
www.gradepro.org)

Results
A total of 3642 records were identified from the systematic search and the review of
reference lists and review articles. After the removal of duplicates, 1862 records were
screened, and 68 full-text articles were reviewed for eligibility. A total of 51 articles were
excluded after full-text review, with the most common reasons for exclusion being: an
inability to isolate the effects of walnuts on the outcome of interest (n=15), for example when
walnuts were provided as part of a suite of dietary changes, the article did not report relevant
outcomes (n=10), and relevant study outcomes were reported in another article included in
the review (n=10) (Figure 1, Supplementary Data 3). This resulted in a total of 17 articles
describing 16 studies included in this review. Through these articles, n=18 effect sizes were
available for inclusion in the meta-analysis (Figure 1).
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Study characteristics
Characteristics of included studies are outlined in Table 1. Eight studies (28,32,38-44) had a
parallel study design, while seven (22,45-50) had a cross-over study design. In addition, one
study (17) included features from both a parallel and cross-over design, where the participants
were randomised to a parallel group (either energy adjusted or ad libitum diet), and each
group was intervened with a walnut-included diet period, and a walnut-excluded diet period.
The duration of the included studies range from four days (46), to one year

(39,43,44)

. Studies

were conducted in Germany (45,50), the United States (17,22,43,46,48,49), Spain (47), Austria (28),
South Africa (38,42), Australia (39,40,44), China (41), and Iran (32). Studies included participants
who were healthy (inclusive of overweight participants)

(22,45,50)

, had metabolic syndrome or

other risk factors for chronic disease (17,38,41-43,46-48), had type 2 diabetes mellitus (28,32,39,40,49),
or included participants with a mixture of these factors (44).
Consumption of walnuts
Walnuts were consumed as whole nuts in 14 of the included studies (17,22,38-50), and as an oil in
two of the studies (28,32). The dose of whole walnuts consumed by participants ranged from 30
grams (1.06 oz) (39-41,44) to 56 grams (1.98 oz) per day (48,49). In three studies walnuts were
consumed to provide a prescribed proportion of dietary energy (ranging from 18 – 22% of
total energy) (38,42,43,47), meaning the dose of walnuts differed between the participants. The
energy value of the walnuts was accounted for in thirteen studies (22,38-50), either by modelling
the energy of the walnuts into the dietary prescription, or by encouraging the participants to
substitute walnuts for other food in their diet. One study (17) included two different
intervention groups, with one group accounting for the added energy from the walnuts,
whereas another group added the walnuts in addition to their regular diet. The background
diets used in the studies included dietary advice based on healthy eating guidelines (for
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example the Australian Guide to Healthy Eating), as well as habitual diets (with the addition
of walnuts for the intervention groups). Control groups typically followed the same
background diet as the intervention group, with the exception of the added walnuts, although
some studies included a comparison food in their control group (for example olive oil (47)).
Risk of bias assessment
The risk of bias assessments are shown in Figure 2 and Supplementary Data 4 and 5. Studies
were determined to have either ‘some concerns’ regarding the risk of bias, or be at ‘high risk’
of bias, with no studies found to be at ‘low risk’ of bias.
Effect of nut consumption on study outcomes
The number of effect sizes and studies, as well as the results of each meta-analysis, are shown
in Table 2 and Figures 3 - 6. Summary data for each study is available in Supplementary Data
6. Walnut consumption did not result in significant differences in the fasting blood glucose,
HbA1c, fasting insulin, or HOMA-IR (Table 2 and Figures 3 - 6). Similar results were found
when conducting sensitivity analyses using Hartung-Knapp-Sidik Jonkman adjustment(26)
(Supplementary Data 7), and when using correlation coefficients of 0.25, 0.5, and 0.75 for
cross-over studies (Supplementary Data 8).
Sensitivity analyses demonstrated that pooling separate intervention groups within the same
study did not substantially the magnitude of the pooled change effect, nor did removing each
individual study, or restricting analysis to studies exploring whole walnuts only
(Supplementary Data 9, 10 and 11, respectively). Sub-group analyses and meta-regression
were conducted where sample size permitted (fasting blood glucose, HbA1c, fasting insulin).
Overall, the sub-group analyses indicated that a similar magnitude of effect was found across
the different sub-groups (Supplementary Data 12). Variation in the magnitude of effect was
observed for the risk of bias (some concerns versus high) and walnut dose (<50g/day versus >
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50g/day) for insulin, however, these results should be interpreted with caution due to the
small number of studies included in the sub-groups. Similar results were observed for the
meta-regression, which found no significant relationship between the outcomes of interest
and the walnut dose, treated as a continuous variable, (fasting blood glucose: p=0.953,
HbA1c: p=0.576; fasting insulin: p=0.711) or study duration, also treated as a continuous
variable (fasting blood glucose: p=0.663; HbA1c: p=0.300; fasting insulin: p=0.375).

Small study effects
Contour funnel plots were generated for outcomes with ten or more effect sizes (fasting blood
glucose, HbA1c, fasting insulin) (Supplementary Data 13). Visual inspection of funnel plots
and the results of Egger’s test did not indicate funnel plot asymmetry.
The quality of the body of evidence
The quality of the body of evidence was determined using GRADE (37) (Supplementary Data
14). The quality of the body of evidence was ‘moderate’ for fasting blood glucose, HbA1c,
and HOMA-IR, after being downgraded due to risk of bias. The quality of the body of
evidence for fasting insulin was ‘low’, as a result of being downgraded for both risk of bias
and inconsistency.

Discussion
This systematic review and meta-analysis pooled the evidence base from randomised
controlled trials examining the impact of walnut consumption on markers of blood glucose
control (fasting glucose, HbA1c, fasting insulin, and HOMA-IR). When compared to control
groups without walnuts, no evidence of a significant effect of walnut consumption on the
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markers of blood glucose control was observed. These results did not appear to be affected by
sensitivity analyses, suggesting the findings were robust across different scenarios for study
inclusion and analysis (18).
The findings are consistent with research on nuts generally. Although there is a strong body
of evidence linking habitual consumption of nuts with reduced risk of cardiovascular disease
(6-8,51)

, and a recent report of reduced risk of cardiovascular disease associated with nut intake

amongst people with T2DM (10), evidence is less consistent for the effect of nut consumption
on incident T2DM and markers of blood glucose control. This may be due to the relative
effects of foods and diets on progression to these two disease states, as well as the study
designs aimed at exposing any relationships. Foods deliver bioactive compounds which have
varying influences on disease mechanisms, and the combination of foods (i.e. diet)
determines the set of nutrients which deliver a form of polypharmacy, or food synergy (52).
Although plant-based diets are by nature high carbohydrate, nuts are largely comprised of fat
and protein. The component effects of nuts on cardiovascular disease have been described
(53)

, one of which is dietary fat modification which has resultant impacts on blood cholesterol

levels, a major risk factor for cardiovascular disease (54). For walnuts specifically, a previous
systematic review found improvements in total and low-density lipoprotein cholesterol levels
with consumption (55). A further prospective study has highlighted the specific areas of heart
disease in which nut consumption may be having its impact (56). On the other hand, although
fatty acids have been implicated in insulin sensitivity (34), glycaemic control is more
immediately influenced by carbohydrate in the diet, so any effect of nuts is likely to be seen
as part of a preventive dietary pattern, as outlined below.
Importantly, study designs vary in terms of the extent to which the total dietary pattern is
controlled, and this may influence the ability to expose the influence of a particular food on
health outcomes (57). Where observational studies (with greater variation in dietary intake)
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form the basis of a systematic review no association between the consumption of nuts and
risk of T2DM (6,8) has been found, but when intervention studies are the focus, conflicting
results emerge (7,11). From a methodological perspective, these inconsistencies may reflect
differences in the eligibility criteria between reviews, resulting in differences in the number
and type of studies included. In view of the above, it is interesting to note that only one
systematic review (7) included an analysis from the PREDIMED trial (58) (which showed a
favourable effect of a Mediterranean diet inclusive of nuts or olive oil on incidence of T2DM
(59)

). Importantly the background diets in the PREDIMED study were controlled and this may

have enabled relationships to be better exposed (57). Nevertheless, conflicting findings are also
reported by systematic reviews of trials examining the impact of nut consumption on markers
of blood glucose control, both in individuals with T2DM (12), and the broader adult population
(13)

. Our findings are consistent with the latter review (13) where it was limited to analyses

specifically examining the impact of walnuts. We build on these findings by including the
most recent studies, considering the broader at risk population, addressing all available
durations of study (22), and using the most up-to-date risk of bias tool(60).
The relative impact of walnuts within a preventive dietary pattern is another way to consider
the food-disease relationship. As walnuts are differentiated from other nuts by their high
polyunsaturated fatty acid content, a desirable impact on cholesterol levels in a low fat diet
would be expected. However, like other nuts they also deliver dietary fibre, phytochemicals,
and a number of vitamins and minerals including folate, niacin, magnesium, and potassium
(61)

. Consumption of tree nuts including walnuts has been found to be associated with

favourable overall nutrient intakes (62,63), and in one study, the provision of walnuts
specifically increased the overall quality of the diets chosen by participants (16,17). Thus, for
cuisine reasons, the inclusion of walnuts may help drive better meal and snack choices
producing a diet more aligned with preventive health outcomes. This behavioural concept
could also be considered in trials of diets related to the prevention of T2DM, where
appreciating the significance of single food choices in a total dietary pattern can be
overlooked.
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From a methodological perspective, the assessment of the risk of bias within individual
studies is essential when considering the overall quality of the body of evidence on a topic
(64)

. We evaluated risk of bias using the Cochrane Collaboration Risk of Bias tool 2.0, which

was updated in July 2019 (23). This updated tool was released to overcome challenges
associated with the previous tool (18), including inconsistent use amongst researchers,
difficulties in determining risk of bias in some domains, and difficulties in assessing overall
risk of bias (60). Applying the 2.0 tool in our review, we found all studies had either ‘some
concerns’ regarding the risk of bias, or were at ‘high risk’ of bias. Potential bias particularly
emerged in relation to the randomisation process, often due to a lack of information on
allocation concealment. It also emerged with the lack of pre-registered protocols detailing
sufficient information to determine if the results were selectively reported. The literature
confirms a general trend for insufficient reporting of allocation concealment in randomised
controlled trials (65), and problems in identifying selective reporting of outcomes due to the
lack of pre-registered study protocols (66). This may reflect the time in which the studies were
conducted relative to demands by the scientific literature for these standards, but this resulted
in downgrading the quality of the body of evidence (evaluated using GRADE (37)), for all
outcomes. These findings suggest a need for more randomised controlled trials with preregistered study protocols and better reporting of all aspects of study methodology in
accordance with current standards.
There were several strengths to this review. It was conducted and reported according to
current guidelines(18,19), and included an evaluation of results using a number of sensitivity
analyses, and examination of the risk of bias using an updated assessment tool. The review
was also not limited by study duration, in comparison to previous reviews on this topic (12,13).
There were also potential limitations, such as the small number of studies available for
inclusion, limiting the generalizability of results and interpretations of the results of the subgroup analyses and meta-regression (known to be influenced by the number of available
observations (18)). Heterogeneity was also observed in participant characteristics, particularly
health status, and in background and control diets. This variation in control diets has been
highlighted as a common issue in nutrition meta-analyses, where adding or removing one
food from the diet will lead to variation in overall kilojoule, macro- and micronutrient
content(67). Furthermore, in order to ensure the effect of walnut consumption could be
isolated, studies which tested walnut consumption in combination with other nuts (for
example mixed nuts) were not eligible for inclusion. While this allowed for the identification
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of the effect of walnut consumption, separated from that of other nuts, this approach resulted
in the exclusion of several studies such the PREDIMED study (58) which used a dose of 30g
mixed nuts, half of which were walnuts, and this may have influenced results. As outlined
previously, none of the included studies were found to be at low risk of bias, which may have
resulted in either under or over-estimating the true intervention effects. In addition,
limitations associated with meta-analysis methodology should be considered. One such
limitation is Simpson’s paradox, an ecological effect which can occur in meta-analyses of
randomised controlled trials, particularly when there are imbalances in the size of study
groups(68). While this appears unlikely in the present review due to the characteristics of the
studies(69), it is possible in some circumstances. Finally, while the present review followed
current guidelines for conducting meta-analyses, it should be noted that alternatives to
random-effects meta-analyses(70-72), and funnel plots and Egger’s test(73) have been proposed.
Further consideration of these advances as a component of research focused on meta-analysis
methodologies is recommended.
This systematic review and meta-analysis did not find evidence of an effect of walnut
consumption on markers of blood glucose control, namely fasting glucose, HbA1c, fasting
insulin, and HOMA-IR. These findings suggest that favourable effects of walnut intake on
health outcomes such as cardiovascular disease observed elsewhere may not be mediated via
improvements in glucose control. Given the high risk of bias observed in the current evidence
base, there is a need for further research on this topic, with a particular emphasis on meeting
current standards for registering and reporting on randomised controlled trials to reduce the
risk of bias.
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Table 1: Characteristics of included randomised controlled trials examining the effect of walnut consumption on blood glucose measures
Citation
and
country

Sample
size for
analysis,
(gender)
204 (M,
F)‡

Mean
age,
years

Mean BMI,
kg/m2

Population

Design

Study
duration,
weeks

Whole
walnut
or oil

Nut
dose

Control
group
details

Background
diet

63 (0.54)§

25.4 (0.29)§

Healthy
(including
overweight)

X

8

W

43g/day

Western
diet

15 (M: 9,
F: 6)

58.0
(2.5)§

36.9 (1.7)§

MetS

X

0.6

W

48g/day

Damasceno
et al.
(2011),
Spain (45)
Holscher et
al. (2018),
United
States (22)

18 (M: 9,
F: 9)

56 ± 13¶

25.7 ± 2.3¶

HC

X

4

W*

18 (M: 10,
F: 8)

53.1
(2.2)§

28.8 (0.9)§

Healthy
(including
overweight)

X

3

W

40 65g/day
§§ (22%
energy)
42g/day

Katz et al.
(2012),
United
States (46)

46 (M: 18,
F: 28)

57.4 +
11.9¶

33.2 + 4.4¶

Overweight
plus risk
factors for
MetS

X

8

W

56g/day

Placebo
meal
containing
2.14%
protein,
48.55%
fat, and
49.31%
carbohydr
ate
35 –
50g/day
virgin
olive oil
Base diet
(17%
protein,
29% fat,
54%
CHO) of
typical
American
foods,
unsupple
mented
with
walnuts
No nuts

Nuts replacing
70g
carbohydrate
or 30g
saturated fat
Isocaloric
diet,
controlled

Bamberger
et al.
(2017),
Germany
(43)
Brennan et
al. (2010),
United
States (44)

Dietary
fat
intake
(%)°
43 – 46

FBG
(units)

HbA1c
(units)

Insulin
(units)

HO
MA
-IR

mg/dL

%

-

-

46.05

mg/dL

-

μIU/mL

-

Mediterranean
-style diet
(isocaloric)

32

mmol/L
•

-

-

-

Base diet
(17% pro,
29% fat, 54%
CHO) of
typical
American
foods. Energy
reduced
proportionally
to incorporate
walnuts

>50

mg/dL

-

-

-

Ad libitum,
participants
advised to
substitute

41.4

mg/dL

-

μIU/mL

HO
MAIR
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Ma et al.
(2010),
United
States (47)

24 (M: 10,
F: 14)

58.1 +
9.2¶

32.5 + 5.0¶

T2DM

X

8

W

56g/day

No nuts

MukuddemPeterson
(2005), and
MukuddemPetersen et
al. (2007),
South
Africa (36,
40)
Mullner et
al. (2014),
Austria (30)

43 (M: 21,
F: 22

I: 45 (95%
CI: 40.4,
50.2)
C: 45
(95% CI:
40.8,
49.3)

I: 36 (95%
CI: 33.3,
38.7)
C: 35.1
(95% CI:
32.8, 37.4)

MetS

P

8

W*

20%
energy
from
walnuts
§§

No nuts

92 (nut
oil: M: 20,
F: 27;
mixed oil:
M: 18, F:
27)

Insulin
treated:
I: 63 (95%
CI: 58.5,
67.5)
C: 66.1
(95% CI:
62.5,
69.7)

Insulin
treated
I: 90.1 (95%
CI: 79.4,
100.7)
C: 93.7
(95% CI:
84.2, 103.1)
‡‡

T2DM
(treated with
OAD or
insulin)

P

1

O

9g
oil/day

Mixed oil
(corn,
sunflower,
linseed
oil)

OAD
treated: I:
62.3 (95%
CI: 59.5,
65.2)
C: 60.9
(95% CI:
57.8,
63.9)
Ad
libitum:
56.5 +
11.7¶
Energy
adjusted:
53.3 +

OAD
treated: I:
86.3 (95%
CI: 79.6,
92.9)
C: 87.6
(95% CI:
81.2–93.9)
‡‡
Ad libitum:
30.0 + 4.0 ¶
Energy
adjusted:
30.2 + 4.1¶

Overweight,
pre-diabetic
or MetS

X••

24

W

56g/day

No nuts

Njike et al.
(2015),
United
States (17)

112 (M:
31, F: 81)

walnuts for
other foods
Ad libitum,
participants
advised to
substitute
walnuts for
other foods
Controlled
feeding
protocol
(isocaloric)

45

mg/dL

%

μIU/mL

HO
MAIR

40.3

mmol/L
•

-

μIU/mL

HO
MAIR

Usual diet

NR

mM•,

%

pM•

HO
MAIR

1. Ad libitum
diet
2. Isocaloric
diet (energy
adjusted for
walnuts)

NR

mg/dL

%

-

-
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11.1¶
Rock et al.
(2016),
United
States (41)

126 (F)

50 (range:
22 - 72)††

33.5 (range:
27 - 40)††

Overweight
and obese

P

52

W

42g/day
¶¶ (18%
energy)

Tapsell et
al. (2004),
Australia
(38)
Tapsell et
al. (2009),
Australia
(37)

35 (M: 21,
F: 16)

I: 57.71 +
8.97¶
C: 59.30 +
7.11¶
54 +
8.7††

I: 30.72 +
3.85¶
C: 30.16 +
4.51¶
I: 33.2 + 4.4
C: 33.0 +
4.0

T2DM

P

26

W

30g/day

T2DM

P

52

W

30g/day

Tapsell et
al. (2017),
Australia
(42)

101 (M,
F) ‡
100 (M,
F) ¶¶

45 (37–
51) ‣
**

32 (29–35) ‣
**

Overweight
and obese
(including
T2DM)

P

52

W

30g/day

Wu et al.
(2010),
China (39)

189 (M:
105, F:
84)

I: 48.2 ±
8.4 ¶
C: 48.6 ±
8.0 ¶

I: 25.7 ± 2.9
¶
C: 25.4 ±
2.4¶

MetS

P

12

W*

30g/day

Wu et al.
(2014),
Germany
(48)

35 (M,
F)‡

60 (1)§
**

24.9 (0.6)§
**

Healthy
(including
overweight)

X

8

W

43g/day

35 (M,F)
‡

Higher fat
(35%
energy)
lower
CHO
(45%
energy)
diet, no
nuts*
<30% fat,
modified
fat†

Hypocaloric
diet (500 1000 kcal/day
deficit)

35

mg/dL

-

μIU/mL

HO
MAIR

<30% fat,
modified fat

~32

-

%

-

-

Low-fat
advice
(weight
maintenan
ce)
Interdiscip
linary
interventi
on
(dietitian,
exercise
physiologi
st,
psycholog
ist
support)†
Bread (no
walnuts
incorporat
ed)

Low-fat
advice
(weight
maintenance)

~34

mmol/L
•

%

μU/L•

Individualized
dietary advice
based on
Australian
Guide to
Healthy
Eating

~33

mmol/L
•

%

-

-

Counselling
and written
materials
based on
American
Heart
Association
guidelines
Western diet
with walnuts
substituted for
saturated fat

36.5

mmol/L
•

%

pmol/L

-

39.2

mg/dL

%

μU/mL

HO
MAIR

No nuts
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(isocaloric)
Zibaeenezha
d et al.
(2016), Iran
(31)

90 (M: 43,
F: 47)

I: 55.5 +
10.75¶
C: 54 +
11.37¶

I: 27.60 +
2.47¶
C: 27.21 +
2.27¶

T2DM

P

12

O

15g/day

No
interventi
on

Dietetic
consultation
on eating a
balanced diet
(advised
according to
weight
maintenance
requirements)

NR

mg/dL

%

°In intervention group
‡Gender breakdown for analysed participants not available
§ Mean (standard error)
¶ Mean + standard deviation
‣Median (interquartile range)
*Study included other intervention group which was not relevant to this review, therefore this group was not included in this analysis
†Treated as comparison group for this analysis
•Unit reported in study, converted to consistent unit for analysis
§§Gram weight for dose sub-analysis based on mid-point of range of doses used
‡‡Body weight (kg) is reported when BMI was not available
††Characteristics reported for participants who met inclusion criteria
••Participants were randomised to one of two parallel groups (ad libitum or calorie adjusted). Within each group participants completed a ‘walnut included’ and ‘walnut excluded’
period in a cross-over design
¶¶ HbA1c
**Characteristics reported for randomised participants
Abbreviations: BMI: body mass index; CI: confidence intervals; F: female; HC: hypercholesterolemia; M: male; MetS: metabolic syndrome; O: walnut oil; OAD: oral antidiabetic
medication; P: parallel; T2DM: type 2 diabetes mellitus; W: whole walnut; X: cross-over

-

-
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Table 2: Changes in outcomes following walnut consumption, compared to control.
Outcome
Fasting blood glucose (mg/dL)
HbA1c (%)

Number of
studies
15
10

Number of
effect sizes
17
12

Number of
participants
1620
1290

Weighted mean difference (95%
CI)
0.331 (-0.817, 1.479), p=0.572
0.031 (-0.001, 0.063), p=0.057

Inconsistency
(I2)
17.4%
16.4%

Fasting insulin (μIU/mL)
HOMA-IR

9
6

10
7

725
471

0.032 (-1.826, 1.889), p=0.973
-0.010 (-0.319, 0.298), p=0.947

53%
6.8%
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Identification

Records identified through
database searching
CINAHL: n=645
Cochrane Central: n=533
MEDLINE: n=1214
PubMed: n= 1248

Additional records identified
through other sources
(n = 2)

Total: n = 3640

Records excluded, with
reasons
(n = 1794 )

Eligibility

Screening

Records after duplicates removed
(n =1862)


Records screened
(n = 1862)

Full-text articles assessed
for eligibility
(n = 68 )



Full-text articles excluded,
with reasons
(n = 51 )



Studies included in
qualitative synthesis
(n = 16 [17 articles])

Included








Studies included in
quantitative synthesis
(meta-analysis)
(n =16 [17 articles];
providing n=18 effect
sizes)

Figure 1: PRISMA flow diagram of study selection

Ineligible intervention:
n=781
Ineligible outcome: n=35
Ineligible population:
n=68
Ineligible study design:
n=910






Conference abstract: n=1
Does not compare walnut
intake to control: n=4
Does not investigate the
effect of walnuts: n=6
Does not report relevant
outcome: n=10
Not appropriate study
design: n=4
Not possible to isolate the
effect of walnuts: n=15
Relevant outcomes
reported in article already
included in review: n=10
Walnut extract: n=1
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Figure 2: Risk of bias assessment as a proportion of total studies
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Figure 3: Difference in fasting blood glucose (mg/dL) between walnut consumption and
control. Diamond indicates weighted mean difference with 95% confidence intervals
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Figure 4: Difference in HbA1c (%) between walnut consumption and control. Diamond
indicates weighted mean difference with 95% confidence intervals.
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Figure 5: Difference in fasting insulin (μIU/mL) between walnut consumption and control.
Diamond indicates weighted mean difference with 95% confidence intervals.
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Figure 6: Difference in HOMA-IR between walnut consumption and control. Diamond
indicates weighted mean difference with 95% confidence intervals.
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